Recommended
product-img
  • Products
  • Discover MP Targets
  • Discover Research Areas
  • mProX™ Human PRKCB Stable Cell Line

    [CAT#: S01YF-1023-PY62]
    Product Category:
    Membrane Protein Stable Cell Lines
    Subcategory:
    Kinase Cell Lines

    Datasheet MSDS Request COA

    Certificate of Analysis Lookup
    To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
    Lot Number

    Made to Order Inquiry

    Inquiry
    Host Cell Type:
    Membrane Protein Engineering:
    Fluorescent Marker:
    Resistance:
    Deliverable:

    Based on this stable cell line, we also provide cell-based in vitro assays to evaluate the effects of your compounds or antibodies.

    Sub Cat Product Name Target Protein Species Host Cell Type Assay Types Inquiry Datasheet
    S01YF-1222-KX441 Magic™ Human PKCβ1(PRKCB1) in Vitro Assay Human Kinase Assay
    S01YF-1222-KX442 Magic™ Human PKCβ2(PRKCB2) in Vitro Assay Human Kinase Assay

    Product Information

    Target Family
    Kinases/Enzyme
    Target Protein Species
    Human
    Host Cell Type
    HEK293;CHO-K1;MKN45
    Target Classification
    Kinase Cell Lines
    Target Research Area
    Cardiovascular Research;CNS Research
    Related Diseases
    Diabetic Macular Edema; Macular Retinal Edema
    Gene ID
    Human:5579
    UniProt ID
    Human:P05771

    Product Properties

    Biosafety Level
    Level 1
    Activity
    Yes
    Quantity
    10⁶ cells per vial
    Applications
    PRKCB (protein kinase C beta) has various applications in different fields. In the field of mental health, PRKCB has been studied in relation to suicide. Research has shown that PRKCB is one of the biomarkers predictive of death by suicide during peak hours of the day. In the treatment of nonalcoholic fatty liver disease (NAFLD), PRKCB is one of the core targets for potential drug development. It plays a role in the PI3K/AKT/mTOR pathway, which is involved in cell growth and tumor proliferation. Additionally, PRKCB has been investigated in the context of breast cancer treatment resistance. A combination of oleanolic acid and maslinic acid, which target PRKCB, has shown enhanced anti-cancer potency in controlling treatment resistance. In pulmonary fibrosis caused by exposure to nickel oxide nanoparticles, PRKCB DNA methylation has been found to be regulated by lncRNA AP000487.1. This regulation affects the Toll-like receptor 4 (TLR4)/MyD88/NF-κB pathway and collagen formation. Finally, in non-small cell lung cancer (NSCLC), the expression of PRKCB has been analyzed for its clinical and prognostic significance. The study found that PRKCB expression is associated with TNM stage and survival probability, making it a potential predictor of prognosis in NSCLC patients.

    Protocols

    Please visit our protocols page.

    Customer Reviews

    There are currently no Customer reviews or questions for mProX™ Human PRKCB Stable Cell Line (S01YF-1023-PY62). Click the button above to contact us or submit your feedback about this product.

    FAQ

    chat Morgan Johnson (Verified Customer)

    How does PRKCB DNA methylation affect pulmonary fibrosis? Jan 23 2020

    chat Patrick Liam (Creative Biolabs Scientific Support)

    PRKCB DNA methylation-mediated JNK/c-Jun pathway plays a role in suppressing Nano NiO-induced pulmonary fibrosis. Jan 23 2020

    chat Skyler Smith (Verified Customer)

    What is the significance of PRKCB in lung adenocarcinoma prognosis? Sep 28 2022

    chat Patrick Liam (Creative Biolabs Scientific Support)

    PRKCB is relevant to the prognosis of lung adenocarcinoma through its involvement in methylation and immune infiltration. Sep 28 2022

    Published Data

    Fig.1 In MKN-45 Cells, PRKCB was the downstream functional gene of hsa_circ_0092306/miR-197-3p.

    Higher cell viability was observed in the PRKCB-overexpressed group, as indicated by the MTT assay. This increase in cell viability was found to be reversible when hsa_circ_0092306 was knocked down or miR-197-3p was overexpressed.

    Ref: Chen, Zihao, et al. "hsa_circ_0092306 targeting miR-197-3p promotes gastric cancer development by regulating PRKCB in MKN-45 cells." Molecular Therapy-Nucleic Acids 18 (2019): 617-626.

    Pubmed: 31689616

    DOI: 10.1016/j.omtn.2019.08.012

    Research Highlights

    Bhagar, R. et al. "Temporal effects on death by suicide: empirical evidence and possible molecular correlates." Discover mental health, 2023.
    In this study, a connection between full moons and increased suicides was empirically analyzed using pre-COVID suicide data from the Marion County Coroner's Office (n = 776). It was found that deaths by suicide were significantly increased during the week of the full moon (p = 0.037), with a stronger effect observed among older individuals (age ≥ 55) (p = 0.019). The analysis also revealed that the hour of the day (3-4 pm, p = 0.035) and the month of the year (September, p = 0.09) with the highest suicide rates were identified. Blood samples from a subset of subjects (n = 45) allowed for an examination of potential molecular mechanisms, revealing that certain blood biomarkers associated with suicidality were enriched in circadian clock genes during specific periods. These findings suggest temporal effects on suicidality, possibly influenced by biological clocks, highlighting the potential for therapeutic interventions related to ambient light, timing, and intensity to reduce suicide rates, in conjunction with psychiatric and addiction treatment approaches.
    Bhagar, R. et al. "Temporal effects on death by suicide: empirical evidence and possible molecular correlates." Discover mental health, 2023.
    Pubmed: 37861857   DOI: 10.1007/s44192-023-00035-4

    Yu, Chenyang. et al. "Exploration of potential targets and mechanisms of naringenin in the treatment of nonalcoholic fatty liver disease through network pharmacology." Medicine, 2023.
    The present study sought to utilize network pharmacology to examine the molecular pathways and potential targets involved in the treatment of nonalcoholic fatty liver disease (NAFLD) with naringenin (NR). By identifying novel targets and potential mechanisms, this research aims to provide new insights and possibilities for the development of NR as a therapeutic agent for NAFLD.
    Yu, Chenyang. et al. "Exploration of potential targets and mechanisms of naringenin in the treatment of nonalcoholic fatty liver disease through network pharmacology." Medicine, 2023.
    Pubmed: 37861538   DOI: 10.1097/MD.0000000000035460

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR CLINICAL PROCEDURES" For licensing inquiries, please contact
    Send Inquiry Send Inquiry
    Inquiry Basket
    compare

    Go to compare